An'erlaifu

An'erlaifu (also known as Anflu or Anerlife) is a preservative-free, unadjuvanted, inactivated split-virion trivalent influenza vaccine (TIV) developed by Beijing Sinovac Biological Products, a subsidiary of Sinovac. First approved in China in 2006, it was the country's first preservative-free trivalent influenza vaccine. It contains 15 µg of hemagglutinin antigen per 0.5 mL dose for each of the three WHO-recommended seasonal influenza strains (typically including influenza A H1N1, influenza A H3N2, and influenza B Victoria lineages). The vaccine is indicated for active immunization to prevent influenza in individuals aged 6 months and older, including infants, children, adults, elderly, and pregnant women.

Brand names

AnerlifeAn'erlaifuAnflu

Other names

TIVinfluenza vaccine (split virion), inactivatedinfluenza virus split vaccinetrivalent inactivated influenza vaccinetrivalent influenza split vaccinetrivalent influenza vaccine (split virion), inactivated